Stockreport

Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Kura Oncology, Inc.  (KURA) 
Last kura oncology, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.kuraoncology.com/investor-relations
PDF LA JOLLA, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precisi [Read more]